Confirmation that heparin is an alternative means of promoting early reperfusion
- 1 January 1998
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Coronary Artery Disease
- Vol. 9 (6) , 335-338
- https://doi.org/10.1097/00019501-199809060-00003
Abstract
New strategies to increase coronary patency rate before primary angioplasty are under discussion. We tested the hypothesis that use of a high dose of a standard heparin bolus could achieve an acceptable rate of re-opening occluded infarct-related arteries thus providing an alternative to chemical thrombolysis before admission of the patient to hospital, and a pretreatment for primary angioplasty. Forty-eight patients who presented within 12 h of acute myocardial infarction with ST segment elevation were assigned randomly to groups to receive aspirin (200 mg orally) and high-dose standard heparin 300 U/kg as an intravenous bolus (n = 25), or aspirin and placebo bolus (n = 23). Thereafter, all patients underwent coronary arteriography to assess their suitability for primary angioplasty. The high-dose heparin group had greater patency rate (Thrombolysis in Myocardial Infarction grade 2 or 3 flow in the infarct-related artery) than the placebo group (52% compared with 13%, P = 0.006). Hemorrhages related to the puncture site that required blood transfusion occurred in two of 25 and in one of 23 patients in the high-dose heparin and placebo groups, respectively. Our study suggests that high-dose standard heparin does have a thrombolytic action when administered as an intravenous bolus.Keywords
This publication has 0 references indexed in Scilit: